Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Handa V, Pati N, Pati U, ul-Hussain M. Multiple liver-specific factors bind to a 64-bp element and activate apo(a) gene. Biochem Biophys Res Commun 2002;292:243-9. [PMID: 11890699 DOI: 10.1006/bbrc.2002.6639] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]

For:	Handa V, Pati N, Pati U, ul-Hussain M. Multiple liver-specific factors bind to a 64-bp element and activate apo(a) gene. Biochem Biophys Res Commun 2002;292:243-9. [PMID: 11890699 DOI: 10.1006/bbrc.2002.6639] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]

Number

Cited by Other Article(s)

Brosolo G, Da Porto A, Marcante S, Picci A, Capilupi F, Capilupi P, Bulfone L, Vacca A, Bertin N, Vivarelli C, Comand J, Catena C, Sechi LA. Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension? Int J Mol Sci 2023;24:13363. [PMID: 37686169 PMCID: PMC10487946 DOI: 10.3390/ijms241713363] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 08/25/2023] [Accepted: 08/25/2023] [Indexed: 09/10/2023] Open

Affiliation(s)

Gabriele Brosolo Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Andrea Da Porto Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) Diabetes and Metabolism Unit, Clinica Medica, University of Udine, 33100 Udine, Italy
Stefano Marcante Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Alessandro Picci Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Filippo Capilupi Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Patrizio Capilupi Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Luca Bulfone Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Antonio Vacca Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Nicole Bertin Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) Thrombosis and Hemostasis Unit, Clinica Medica, University of Udine, 33100 Udine, Italy
Cinzia Vivarelli Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.)
Jacopo Comand Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Cristiana Catena Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy
Leonardo A. Sechi Department of Medicine, University of Udine, 33100 Udine, Italy; (A.D.P.); (S.M.); (A.P.); (F.C.); (P.C.); (L.B.); (A.V.); (N.B.); (C.V.); (J.C.); (C.C.) European Hypertension Excellence Center, Clinica Medica, University of Udine, 33100 Udine, Italy Diabetes and Metabolism Unit, Clinica Medica, University of Udine, 33100 Udine, Italy Thrombosis and Hemostasis Unit, Clinica Medica, University of Udine, 33100 Udine, Italy

Collapse

Helbig KJ, George J, Beard MR. A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. J Clin Virol 2005;32:137-43. [PMID: 15653416 DOI: 10.1016/j.jcv.2004.10.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2004] [Accepted: 10/04/2004] [Indexed: 11/22/2022]

Abstract

BACKGROUND

Chemokines are strong candidate genes for outcome of HCV infection. I-TAC is a chemokine known to be involved in the inflammatory process of HCV infection, and its expression is upregulated in chronic hepatitis C (CHC).

OBJECTIVES

The aim of this study was to investigate genetic variability in the I-TAC promoter and to determine the correlation of these variants with HCV disease progression.

STUDY DESIGN

I-TAC genotyping was performed in 60 chronic HCV patients and 60 controls using GeneScan analysis. Functional analysis of the I-TAC promoter was performed with the aid of luciferase reporter constructs transfected into Huh-7 cells or Huh-7 cells harbouring HCV genomic and sub-genomic replicons. Cytokine induced production of I-TAC from whole blood cultures was measured using enzyme-linked immunosorbent assay (ELISA).

RESULTS

Sequencing of approximately 1 kb upstream of the I-TAC gene start codon revealed the presence of a novel 5 bp deletion mutant (-599del5) in a number of chronic HCV patients. Analysis of the functional potential of this deletion revealed no transcriptional change in Huh-7 cells transfected with luciferase reporter constructs, and this was confirmed in cytokine stimulated whole blood cultures where similar levels of I-TAC were liberated regardless of -599del5 genotype. Conversely, the -599del5 deletion variant significantly reduced transcriptional activity of the I-TAC promoter in the presence of replicating HCV. The distribution frequency of the allele was found to be significantly increased in a chronically HCV infected population compared to healthy controls.

CONCLUSIONS

The novel I-TAC -599del5 promoter polymorphism is a functional variant in the presence of replicating HCV. Furthermore, this deletion mutant is significantly increased in a chronic HCV cohort and may predispose to HCV disease susceptibility.

Collapse

Negi S, Singh SK, Pati N, Handa V, Chauhan R, Pati U. A proximal tissue-specific module and a distal negative regulatory module control apolipoprotein(a) gene transcription. Biochem J 2004;379:151-9. [PMID: 14680477 PMCID: PMC1224047 DOI: 10.1042/bj20030985] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2003] [Revised: 11/24/2003] [Accepted: 12/18/2003] [Indexed: 01/07/2023]